Berger LA et al. Identification of a High-Level MET Amplification in CTCs and cfTNA of an ALK-Positive NSCLC Patient Developing Evasive Resistance to Crizotinib. J Thorac Oncol 2018; Dec;13(12):e243-e246. DOI: 10.1016/j.jtho.2018.08.2025 I2
Wagener-Ryczek S et al. Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors. BMC Cancer 2020; May 12;20(1):408. doi: 10.1186/s12885-020-06920-3
Michels S et al. Genomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung Cancer. JCO Precis Oncol 2019; Mar 27;3. doi: 10.1200/PO.18.00210